In the present study, we investigated the effect of retinoids on Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines (LCLs), since these cells closely resemble those that give rise t o EBV-related lymphoproliferative disorders in the immunosuppressed host. All six compounds tested inhibited LCL proliferation with no significant direct cytotoxicity, but 9-cis-retinoic acid (RA), 13-cis-RA, and all-trans-RA (ATRA) were markedly more efficacious than Ro40-8757, Ro13-6298, and etretinate. The antiproliferative action of the three most effective compounds was confirmed in a large panel of LCLs, thus appearing as a generalized phenomenon in these cells. LCL growth was irreversibly inhibited even after 2 days of treatment at drug concentrations corresponding t o therapeutically achievable plasma levels. Retinoid-treated cells showed a marked downregulation of CD71 and a decreased S-phase compartment with a parallel accumulation in Go/ G, phases. These cell cycle perturbations were associated with the upregulation of p27 Kipl, a nuclear protein that controls entrance and progression through the cell cycle by ETINOIDS ARE A CLASS OF compounds consisting of retinol (vitamin A) and its derivatives and synthetic analogs. Natural retinoids are fundamental for many physiologic processes, such as reproduction, growth, and cellular differentiation. These effects are mediated by binding to and activating two different types of nuclear receptors, the retinoic acid (RA) receptors (RARs) and retinoid X receptors (RXRs).' All-trans-RA (ATRA) is a high-affinity ligand for RARs only, whereas 9-cis-RA is a high-affinity ligand for both RARs and RXRs.' RAR-RXR heterodimers activate the transcription of target genes in response to ATRA or 9-cis-RA, whereas RXR-RXR homodimers transactivate in response to 9-cis-RA. The wide biologic effects of retinoids have led to investigation of the possible efficacy of these molecules in the treatment of neoplastic diseases. Preclinical studies have demonstrated that retinoids can inhibit the growth of a number of tumor cell lines, either independently of or subsequently to the induction of cell differentiati~n.~ These observations prompted several investigators to use RAs in the chemoprevention of human malignancies, and more recently as therapeutic agent^.^,^ Results in this respect have been impressive, particularly those concerning the treatment of acute promyelocytic l e~k e m i a ,~,~ cervical cancer; and metastatic squamous carcinoma of the skin.8
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In the present study, we investigated the effect of retinoids on Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines (LCLs), since these cells closely resemble those that give rise t o EBV-related lymphoproliferative disorders in the immunosuppressed host. All six compounds tested inhibited LCL proliferation with no significant direct cytotoxicity, but 9-cis-retinoic acid (RA), 13-cis-RA, and all-trans-RA (ATRA) were markedly more efficacious than Ro40-8757, Ro13-6298, and etretinate. The antiproliferative action of the three most effective compounds was confirmed in a large panel of LCLs, thus appearing as a generalized phenomenon in these cells. LCL growth was irreversibly inhibited even after 2 days of treatment at drug concentrations corresponding t o therapeutically achievable plasma levels. Retinoid-treated cells showed a marked downregulation of CD71 and a decreased S-phase compartment with a parallel accumulation in Go/ G, phases. These cell cycle perturbations were associated with the upregulation of p27 Kipl, a nuclear protein that controls entrance and progression through the cell cycle by ETINOIDS ARE A CLASS OF compounds consisting of retinol (vitamin A) and its derivatives and synthetic analogs. Natural retinoids are fundamental for many physiologic processes, such as reproduction, growth, and cellular differentiation. These effects are mediated by binding to and activating two different types of nuclear receptors, the retinoic acid (RA) receptors (RARs) and retinoid X receptors (RXRs).' All-trans-RA (ATRA) is a high-affinity ligand for RARs only, whereas 9-cis-RA is a high-affinity ligand for both RARs and RXRs.' RAR-RXR heterodimers activate the transcription of target genes in response to ATRA or 9-cis-RA, whereas RXR-RXR homodimers transactivate in response to 9-cis-RA. The wide biologic effects of retinoids have led to investigation of the possible efficacy of these molecules in the treatment of neoplastic diseases. Preclinical studies have demonstrated that retinoids can inhibit the growth of a number of tumor cell lines, either independently of or subsequently to the induction of cell differentiati~n.~ These observations prompted several investigators to use RAs in the chemoprevention of human malignancies, and more recently as therapeutic agent^.^,^ Results in this respect have been impressive, particularly those concerning the treatment of acute promyelocytic l e~k e m i a ,~,~ cervical cancer; and metastatic squamous carcinoma of the skin. 8 With regard to lymphoproliferative disorders, retinoids have been reported to be effective alone or in combination therapies, mainly in patients with T-cell malignancie~.~"' Nevertheless, in vitro and in vivo studies aimed at evaluating the possible role of retinoids in the treatment of other lymphoid malignancies are relatively few. In particular, available data on the effects of retinoids on in vitro proliferation of normal, activated, or transformed B lymphocytes are limited and controversial, with both stimulatory and inhibitory effects having been Upon infection with Epstein-Barr virus (EBV), B lympho- inhibiting several cyclin/cyclin-dependent kinase complexes. Unlike what is observed in other systems, the antiproliferative effect exerted by retinoids on LCLs was not due to the acquisition of a terminally differentiated status. In fact, retinoid-induced modifications of cell morphology, phenotype (downregulation of CD19, HLA-DR. and [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . and increased expression of CD38 and c-lg), and IgM production were late events, highly heterogeneous, and often slightly relevant, being therefore only partially indicative of a drugrelated differentiative process. Moreover, EBV-encoded EBV nuclear antigen-2 and latent membrane protein-l proteins were inconstantly downregulated by retinoids, indicating that their growth-inhibitory effect is not mediated by a direct modulation of viral latent antigen expression. The strong antiproliferative activity exerted by retinoids in our experimental model indicates that these compounds may represent a useful tool in the medical management of EBV-related lymphoproliferative disorders of immunosuppressed patients.
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cytes become able to proliferate indefinitely in culture. These immortalized lymphoblastoid cell lines (LCLs) are nontumorigenic in nude mice" and resemble activated normal B cells in the expression of activation markers (CD23, CD30, CD39, CD40, and CD70) and adhesion molecules (CD1 la, CD18, CD54, and
In addition, LCLs express at least six nuclear EBNAs and three membrane LMPs EBVencoded latent antigens. Two of them, EBV nuclear antigen-2 (EBNA-2) and latent membrane protein-l (LMP-l), have been shown to play a crucial role in EBV-induced immortalization of B l y r n p h o~y t e s .~~~~~ On these grounds, EBV-infected LCLs constitute a suitable model to investigate the effects of various compounds on B-cell growth and activation. More importantly, these cell lines show characteristics similar to those of EBV-associated B-cell lymphoproliferative disorders that arise in immunosuppressed individual~.'~.'~ Due to the impairment of cytotoxic T-cell responses, these patients may develop oligoclonal or monoclonal proliferations of EBV-infected B lymphocytes showing expression of EBNA-2, LMP-1, and the same activation markers detected in LCLs grown in
The present study was aimed at verifying the in vitro biologic basis that could support the clinical use of retinoids in the treatment of human EBV-related B-cell lymphoproliferative disorders, particularly those arising in the context of immune deficiency. To this end, we characterized the effects of six retinoids, namely 13-cis-RA, ATRA, 9-cis-RA, Ro40-8757, Ro13-6298, and etretinate, on the proliferation of a series of EBV-positive LCLs. Possible differentiating effects of retinoids on LCLs were also investigated by morphologic, phenotypical, and functional analyses. Finally, we wished to determine whether LCL exposure to retinoids might affect the expression of EBV-encoded latent antigens such as EBNA-2 and LMP-1, which drive the proliferation of these immortalized B lymphocytes.**~*'
MATERIALS AND METHODS
Retinoids. ATRA, 9-cis-RA, Ro40-8757, Ro13-6298, and etretinate were provided by Roche (Basel, Switzerland); 13-cis-RA was purchased from Sigma Chemical CO (Milan, Italy). The compounds were dissolved in dimethylsulfoxide (DMSO) at lo-' m o m and diluted in the culture medium so that the final concentration of the solvent was not greater than 0.01 % (vol/vol). Retinoids were handled under subdued light. The stock solutions were stored at -20°C protected from light and oxygen.
Cell lines and culture conditions. The human EBV-immortalized B-LCLs DAA3, DRA12, HDE14, and HDNS13 were established in our laboratory by infecting peripheral blood lymphocytes of healthy donors (DAA3 and DRA12) or patients with Hodgkin's disease (HDE14 and HDNS13) with spent supernatant of the virusproducing B95.8 marmoset cell line as previously described." All cell lines were cultured in RPM1 1640 supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL penicillin, 100 pg/mL streptomycin, and 20 mmol/L L-glutamine and maintained in a humidified 5% CO, incubator at 37°C.
Cell proliferation assay. Proliferation assays were performed in 96-well plates in triplicate cultures in the presence of various dilutions of retinoids. Cells were seeded at an initial density of IO4 cells per well in 200 pL medium. Appropriate DMSO dilutions were used as controls. DMSO did not affect proliferation of any cell line. At the time points indicated, cultures were pulsed with 1 pCi [3H]-methylthymidine (specific activity, 25 Ci/mmol: Amersham International, Bucks, UK) for 6 hours and subsequently harvested on nitrocellulose filters. Radioactivity measured in a liquid scintillation counter, and results are expressed as the mean + counts SD per minute of triplicate wells. To determine the number of viable cells, nine aliquots per time point were counted in a Biirker chamber in the presence of trypan blue.
Cell cycle analysis. The influence of retinoids on cell cycle parameters was investigated by flow cytometry after propidium iodide staining. To record a DNA histogram, approximately 10' cells were pelleted, resuspended in 500 pL phosphate-buffered saline (PBS), and fixed with 1 mL ice-cold ethanol for 25 minutes. Cells were then extensively washed and resuspended for 30 minutes at room temperature in 1 mL 50-pg/rnL propidium iodide in 0.1 % sodium citrate, 0.01% Nonidet, and 0.01 mg/mL ribonuclease A. Cells were then measured immediately using a FACScan (Becton Dickinson, Mountain View, CA); the excitation wavelength in the cytometer was 488 nm, and red (610 nm) fluorescence was recorded. Data acquisition ( lo4 events for each sample) and analysis were performed using CELLFIT software (Becton Dickinson).
Apoptosis detection. leupeptin, 1 p *mL" aprotinin, 0.2% Triton X-100, and 0.3% Nonidet P-40. After an incubation of 20 minutes at 0°C. the extracts were centrifuged for 30 minutes at 12,000 rpm at 4°C. Protein concentration in the lysate was determined by the Bio-Rad protein assay kit (Bio-Rad Laboratories, Richmond, CA). Aliquots of the supernatant were mixed with 2X SDS sample buffer (150 mmoll. Tris. 30% glycerol, 3% SDS, 1.5 mg/100 mL bromophenol blue dye, and 100 mmol/L DTT) and denatured at 100°C for 10 minutes. Equivalent amounts (50 p g ) of protein were separated on 10% SDS-polyacrylamide gel electrophoresis (PAGE) gels and transferred onto nitrocellulose membrane. Ponceau S staining was performed to confirm that equal amounts of total protein were present in all the lanes. The membrane was blocked with 5% dry milk in PBS for 1 hour at room temperature and incubated with anti-p27 Kip-l ( I :2,500) overnight at 4°C. After three washes with 5% milk for 5 minutes, the membranes were incubated for 1 hour at room temperature with an appropriate horseradish peroxidase-linked secondary antibody ( I : 1,000). Final washes were performed in 5% milk for 15 minutes. PBSTriton X-l00 for 5 minutes (three times), and distilled water for 5 minutes, Immunolabeled bands were detected with the ECL Western blotting detection system (Amersham).
Morphologic analysis. Retinoid-induced changes in LCL morphology were investigated on May-Griinwald-Giemsa-stained cytospin preparations. One thousand cells per sample were examined.
Antibodies. The monoclonal antibodies used in this study were CD19, CD21, CD23, CD71, and anti-HLA-DR (Becton Dickinson, Milan, Italy); CDlla, CD54, and CD58 (Immunotech, Marseille, Cell surface immunojuorescence analysis. Cell surface immunofluorescence analysis was performed as previously described." Briefly, after preincubation for 30 minutes at 4°C in binding buffer (10% rabbit serum in PBS), cells (5 X lo5) were incubated with saturating concentrations of the primary monoclonal antibody for 30 minutes at 4°C. After three washes in PBS, samples were incubated for an additional 30 minutes at 4°C with optimal dilutions of FITCconjugated second-step antibody. Samples were then washed three times with PBS and fixed in 1% buffered paraformaldehyde. Isotypematched controls were used to determine nonspecific binding. All flow-cytometric analyses were performed on a FACScan using Lysis I1 software (Becton Dickinson).
Intracellular immunojuorescence analysis.
The expression of intracellular antigens (c-Ig, p27 Kipl, LMP-1, and EBNA-2) was investigated by immunofluorescence on cells permeabilized and fixed using ORTHO PermeaFix (Ortho, Milan, Italy). Briefly, 5 X IO5 cells were incubated with 2 mL ORTHO PermeaFix (1:2 dilution) at room temperature for 40 minutes. After centrifugation (400g for 10 minutes), the supernate was aspirated and pellets were resuspended and kept for 10 minutes at room temperature in 2 mL 10% PBS/BSA. Cells were then centrifuged, the supernate was discarded, and staining was performed as already described. Optimal dilutions of anti-LMP-l and anti-EBNA-2 antibodies were determined using the EBV-negative Burkitt's lymphoma-derived cell line, DG75, as a negative control. Appropriate anti-p27 Kipl monoclonal antibody dilution was assessed using resting or PHA-activated peripheral blood lymphocytes as positive and negative controls, respectively. The Jurkat T-cell line was used as a negative control to determine the working dilution of anti-Ig antibody. l g production. To measure IgM production, enzyme-linked immunosorbent assay (ELISA) plates (Costar, Milan, Italy) were coated overnight at 4°C with a rabbit anti-human IgM (DAKO) diluted 1: 12,800 in 0.2 mom carbonate buffer (pH 9.6). After washing with 0.1% Tween 20 in PBS (PBS-T), plates were preincubated with 1% gelatin in PBS for 1 hour at room temperature. Culture supernatant dilutions in PBS-T were then incubated in triplicate for 2 hours at room temperature. After five washes with PBS, a peroxidaseconjugated rabbit antihuman IgM diluted 1:800 in PBS-T was added and the plates were kept for 2 hours at room temperature. After five washes with PBS-T, the plates were allowed to develop for 30 minutes with ABTS substrate in 0.1 moVL citrate buffer (pH 4) and 0.003% H202. Extinction was measured at 405 nm. Ig production levels were calculated according to a calibration curve obtained with human standard IgM and starting from a concentration of 400 ng/ mL. The detection limit of the assay was 1.56 ng/mL.
Statistical analysis. The significance of immunophenotypic changes between retinoid-treated LCLs and control cultures was evaluated using the Student's t-test and Kolmogorov-Smirnov analysis.
RESULTS
Antiproliferative effects of different retinoids on EBV-positive LCLs. Two EBV-infected LCLs, HDE14 and DAA3, were treated with 13-cis-RA, ATRA, 9-cis-RA, Ro40-8757, Ro13-6298, and etretinate at concentrations ranging from to mom; cell proliferation was evaluated by 3H-thymidine incorporation after 3, 5, 7, and 10 days of treatment. All six compounds inhibited LCL proliferation, but with different efficacy (Figs 1 and 2) .
ATRA, 13-cis-RA, and 9-cis-RA were the most powerful inhibitors of EBV-positive lymphoblastoid B-cell proliferation. In fact, after 3 days of treatment, a significant dosedependent reduction in 3H-thymidine uptake was already detectable in both HDE14 and DAA3 cell lines. The antiproliferative activity of these compounds was even more evident later, with almost equivalent effects induced by all doses at day 5 for HDE14 and at day 7 for DAA3 cells. Maximal growth inhibition was reached at day 5 for HDE14 and at day 10 for DAA3 cells. The analysis was extended to 13 other EBV-infected LCLs of various origin, including three cell lines that, in addition to DAA3, were able to form subcutaneous tumors when transplanted (10' cells) in SCID mice (data not shown). Treatment with m o m ATRA, 9-&-RA, or 13-cis-RA induced a significant decrease in 3H-thymidine uptake in all cell lines, with inhibition at day 6 ranging from 49% to 84% compared with controls (data not
. These data indicate that the antiproliferative effect of retinoids on EBV-carrying LCLs is probably a generalized phenomenon.
Also, R013-6298 was characterized by a dose-dependent antiproliferative activity on LCLs, even if with less pronounced effects at all doses compared with ATRA, 13-cis-RA, and 9-cis-RA (Figs 1 and 2 ). Etretinate exhibited a lower growth-inhibitory activity than Ro13-6298, still in a dose-dependent fashion. In fact, although no significant inhibition of 3H-thymidine incorporation was observed at the dose of 3 X m o m , higher etretinate concentrations were increasingly effective (Figs 1 and 2) . Ro40-8757 induced a dose-dependent reduction of 3H-thymidine incorporation in the HDE14 LCL only after 10 days of treatment, whereas DAA3 cells displayed significantly reduced counts only at the highest concentration mom) of this compound (Figs 1 and 2) . These results were reproduced in four different experiments. With regard to responsiveness to the antiproliferative effects of retinoids, these findings indicate that the HDE14 LCL is relatively more sensitive than DAA3, displaying earlier and more pronounced responses at all doses.
Evaluation of cell viability by trypan blue exclusion showed that although control cultures displayed a progressive increase in growth rate, the number of live HDE14 and DAA3 cells did not significantly change after 3, 6, and 10 days in the presence of either mol& ATRA, 9-cis-RA, or 13-&-RA (Fig 3) . In addition, after 3 days of treatment, both HDE14 and DAA3 LCLs showed a ratio between live and dead cells that was almost superimposable on that of control cultures (data not shown). These findings confirmed that retinoids exert a significant antiproliferative activity on EBV-infected LCLs, and indicated that the growth inhibition induced by these compounds is probably not the consequence of direct cytotoxic effects.
We also wished to verify whether the antiproliferative effect of retinoids was partly dependent on the induction or enhancement of apoptotic phenomena. No DNA fragmentation was observed by gel electrophoresis in DAA3 and HDE14 cells cultured for 6, 10, and 20 days with either m o m 13-cis-RA or 0.01 % DMSO. In addition, no apoptotic subdiploid pre-Go/GI peak was detected by flow cytometry after propidium iodide staining in the two LCLs following 3, 7, 10, and 14 days of treatment. The same cells were also investigated simultaneously by enzymatic labeling of apoptosis-induced DNA strand breaks (TUNEL, or TdT-mediated dUTP nick end labeling). The analysis confirmed that DAA3 and HDE14 cells did not undergo detectable apoptosis, either spontaneous or retinoid-induced (data not shown).
Dose-dependent reversibility of retinoid-induced antiproliferative effects on LCLs. When treated with m o m 13-cis-RA or ATRA for 2 days, three different LCLs (HDE14, DAA3, and HDNS13) showed no growth recovery after drug withdrawal over a period of 14 days (Fig 4) as resulted from 3H-thymidine uptake and microscopy cell count. Conversely, lower concentrations of retinoids (lo-' m o m ) were not able to induce an irreversible inhibition of LCL proliferation, even if the treatment was prolonged up to 6 days (data not shown). Consistent with the observation that retinoids are not cytotoxic for LCLs, exposure to different drug concentrations did not significantly modify the number of viable cells, which was in any case sufficient to allow LCL proliferation. On these grounds, we can exclude that the reversibility of LCL growth inhibition might be due to a dose-related differential reduction in the number of viable cells. Similar results were obtained with 9-cis-RA (data not shown).
Retinoid treatment decreases the proportion of cycling EBV-positive lymphoblastoid cells. The effect of retinoids on cell cycle parameters was investigated in four different LCLs (DAA3, DRA12, HDE14, and HDNS13) after 3, 7, 10, and 14 days of treatment with m o m 13-cis-RA. All treated LCLs showed a progressive reduction in the number of S-phase cells, with a concomitant increase in the number of cells in Go/GI phases (Table 1) . Nevertheless, only a slight decrease of S-phase cells was observed after 3 days of treatment when retinoid was shown to induce a significant reduction in 'H-thymidine uptake and growth rate (Figs 1,2, and 3 , and data not shown). These findings suggest that besides inducing a progressive decrease of the S-phase compartment, retinoids probably also slow the progression through cell cycle phases.
We also evaluated the cell-surface expression of the transferrin receptor (CD71), a molecule highly expressed by actively cycling cells. Consistent with the lower proliferation rate of EBV-positive LCLs treated with retinoids, a significant downregulation of CD71 expression was observed in DAA3 and HDE14 cells cultured for 6 days with mol/ L 13-cis-RA (Table 2 and Fig 5) . Retinoid treatment of both LCLs also induced a marked increase in the expression levels of p27 Kip-l (Fig 5) , a nuclear protein that inhibits the kinase activity of various cyclidcyclin-dependent kinase (cdk) complexes.29 After 13-cis-RA treatment, p27 Kip-l upregulation was more prominent in HDE14 than in DAA3 cells, a finding consistent with the more pronounced reduction of the S-phase compartment displayed by the HDE14 LCL. Similar findings were obtained following immunoblotting analysis (Fig 6) . Furthermore, p27 Kip-l expression levels closely correlated with the proliferation rates of LCLs treated with 13-cis-RA doses able to induce either a reversible or irreversible inhibition of cell growth. In fact, the remarkable increase in p27 Kip-l expression induced by mol/L 13-&-RA persisted up to 10 days after drug removal (data not shown). Conversely, after exposure to retinoid concentrations (lo-' molL for 6 days) responsible for a reversible growth inhibition, DAA3 and HDE14 LCLs displayed only a temporary increase in p27 Kip-l expression levels, which progressively returned to basal levels concomitantly with the recovery of cell proliferation (data not shown).
Effects of retinoids on B-LCL differentiation. Untreated DAA3 and HDE14 cells showed great morphologic heterogeneity. In both LCLs, approximately 70% to 80% of cells had a lymphocyte-like appearance: they were rounded, small or medium in size, and showed scanty or moderately abundant basophilic cytoplasm, barely vacuolated, with round or twisted nuclei and condensed chromatin, usually with unapparent nucleoli (Fig 7) . By contrast, about 20% to 30% of the cells were approximately twice as large, irregularly use only. shaped, with abundant pale cytoplasm containing evident vacuoli and a more open chromatin pattern with prominent nucleoli (Fig 7) . After 6 days of treatment with m o m 13-cis-RA, a clear inversion between the relative ratio of these two main cell subsets was observed in both cell lines (Fig 7) . Despite a certain degree of basal morphologic heterogeneity, a similar marked increase in the number of cells with larger size was observed also in other LCLs treated with 13-&-RA. Although retinoid-treated LCLs did not display cytologic features fully compatible with those of terminally differentiated plasma cells, the morphologic changes observed were reproducible, distinct phenomena suggesting a possible transition toward functionally more active elements.
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When compared with LCLs cultured with DMSO, retinoid-treated DAA3 and HDE14 cells showed modifications of the immunophenotypic profile (Table 2 and Fig 8) . Particularly relevant in both LCLs were the upregulation of CD38, B-B4 (a marker of Ig-secreting plasma cells), and cytoplasmic Ig (c-Ig) and downregulation of CD19, HLA-DR, and S-Ig, and for HDE14, CD24 and CD21 ( Table 2) . Significantly increased levels of CD38 expression were observed in two other LCLs (DRA12 and HDNS 13), which, however, displayed only a slight downregulation of CD19, HLA-DR, and S-Ig (data not shown). In addition, no significant modification of CD10 and CD77 expression levels was detected in DAA3 and HDE14 LCLs treated with retinoids, ruling out possible shifts toward a Burkitt's lymphoma-like phenotype.
Possible differentiating effects of retinoids on LCLs were further investigated at the functional level by analyzing Ig production in culture Supernatants of cells treated with moVL 13-cis-RA. Retinoid treatment did not affect IgM production in the DRA12 LCL, whereas a slight increase in IgM content was detected in the supernatant of HDE14 and HDNS13 cells cultured with 13-cis-RA (Fig 9) .
Effects of retinoids on EBV-encoded antigen expression. We wished to determine whether LCL growth inhibition induced by retinoids was mediated by downregulation of EBV-encoded antigens, which are crucial for the immortalization of B lymphocytes. To this end, we investigated the expression of LMP-1 and EBNA-2 in four different LCLs (DAA3, DRA12, HDE14, and HDNS13) following retinoid treatment ( mol/L 13-cis-RA) by immunofluorescent staining after cell permeabilization and fixation and subsequent flow-cytometric analysis. After 4 days of retinoid treatment, when LCL proliferation was significantly inhibited, EBNA-2 and LMP-1 expression levels were unchanged or only slightly downregulated (data not shown). These findings suggest that the antiproliferative effect of retinoids on LCLs is apparently not mediated by a direct influence of these compounds on viral latent antigen expression. After 6 days of treatment, all LCLs displayed lower levels of EBNA-2 and LMP-1 expression than control cultures (Table 3) , although 
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downregulation was significant only in DAA3 and HDE14 cells (Fig IO) . When drug exposure was prolonged up to 25 days, a further reduction of EBNA-2 and LMP-I was observed in DAA3 and HDE14 cells, whereas DRAI2 and HDNS 13 LCLs still showed no significant modifications (Table 3) . Among the activation antigens and adhesion molecules whose expression has been related to EBV infection, only CD30 was downregulated in all cell lines after a 6-day treatment (Table 2 , and data not shown), whereas no relevant modifications of CD23, CD40, CD1 la, CD54, and CD58 were observed (data not shown).
DISCUSSION
The antiproliferative effect of retinoids is well known. In fact, a number of experimental data indicate that cells of various origin. either normal or transformed, decrease their growth rate upon exposure to these compounds.' Neverthe- less, extensive studies on the effects of retinoids on B lymphocytes are relatively few and the results obtained are not conclusive, with both stimulatory and inhibitory effects on these cells reported.".lX
In the present study, we provide evidence that retinoids significantly inhibit the proliferative activity of EBV-infected lymphoblastoid B cells in vitro. All the retinoids tested exerted antiproliferative effects on LCLs, but with variable efficacy. Among the six compounds investigated, 13-cis-RA. 9-cis-RA, and ATRA provided the strongest antiproliferative effect, being active at concentrations as low as IO-' m o l L These retinoids displayed similar antiproliferative activity, without any significant direct cytotoxic effect on LCLs. Of note, the inhibitory effect on LCL growth exerted by retinoids probably represents a generalized phenomenon, since the proliferation of all 15 lines tested was inhibited by at least 50% after 6 days of treatment with 13-cis-RA. With
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DMSO 13-cis-RA DMSO 13-cis-RA regard to the other retinoids analyzed, etretinate and Ro13-6298 were less active than 13-cis-RA, 9-cis-RA, and ATRA, showing a markedly dose-dependent antiproliferative activity. The arotinoid Ro40-8757 was able to reduce LCL mitotic activity only after 10 days of treatment, again in a doserelated fashion. These findings, together with what was observed in other experimental models,'" are consistent with a delayed antiproliferative effect of Ro40-8757, which might be related to the lack of binding to nuclear RA receptors of this ar~tinoid.~' Interestingly, in the experimental conditions used, the proliferative block exerted by retinoids on LCLs cultured in vitro appears to be irreversible, with 2 days of treatment with IO-' mol/L 13-cis-RA being sufficient to induce a permanent growth arrest. Conversely, exposure to lower retinoid concentrations (10 -* mol/L), even if prolonged up to 6 days, 
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induced only a temporary inhibition of LCL growth. It is worth considering that retinoid concentrations ( mom) able to induce an irreversible block of LCL proliferation in vitro are pharmacologically achievable in humans with oral systemic therapy. 32 Retinoid treatment of LCLs was associated with a progressive reduction of the S-phase compartment and a concomitant increase in the number of cells in Go/GI phases. Nevertheless, although retinoid-induced growth inhibition was evident from the third day of treatment, a significant redistribution of cells among the different cell cycle compartments was detectable only after 1 week of culture with the drug. Therefore, besides reducing the S-phase compartment of EBV-positive LCLs, retinoids probably also affect cell cycle kinetics, perhaps prolonging the relative duration of one or more phases, as observed in other ~y s t e m s .~~.~~ Consistent with the reduction of the mitotic rate induced by retinoids, 13-cis-RA-treated LCLs displayed a significant downregulation of CD71, an antigen strictly related to cell-proliferating activity. Moreover, retinoid treatment was associated with a marked upregulation of p27 Kipl, a growth-inhibitory nuclear factor able to block the kinase activity of several cyclidcdk complexes.29 Furthermore, p27 Kipl expression varied according to the proliferative activity of LCLs, showing a permanent increase in cells irreversibly growth-inhibited and a progressive decrease to basal levels when cell proliferation restarted. These findings are in keeping with the recent observation that, concomitant with the inhibition of cell proliferation, p27 Kipl expression increases after RA exposure in HL60 and RA receptor-transfected K562 cells. 35 With regard to lymphocytes, recent evidence has suggested that p27 Kipl is probably crucial to control transition from G, to G, of these cells, thus modulating entry into and exit from the cell cycle.35 On these grounds, our results are therefore consistent with the possibility that p27 Kipl may mediate the reduction of the S-phase compartment induced by retinoids on EBV-infected LCLs, probably affecting Go-G, transition.
The analysis of morphologic, phenotypic, and functional characteristics related to the differentiation of B lymphocytes showed that in some cell lines, retinoids induced changes compatible with a shift toward a slightly more differentiated phenotype. In fact, upon retinoid exposure, certain LCLs showed higher numbers of larger elements, displaying a significant increase in CD38, B-B4, and c-Ig expression levels concomitantly with a downregulation of CD19, HLA-DR, S-Ig, and an enhanced Ig production. Nevertheless, in no instance did retinoid-treated LCLs acquire features of typical, fully mature plasma cells, even after several days of continuous treatment. Moreover, retinoids induced strong antiproliferative effects also in lines showing no relevant change in terms of differentiation-related features. These findings indicate that, unlike what was observed in other systems, the antiproliferative activity of retinoids is not dependent on the induction of a terminally differentiated status of LCLs. However, it cannot be ruled out that these modifications are a consequence rather than a cause of the status of nonproliferating cells induced by retinoids. In fact, for terminal differentiation to occur, cells must be removed from the cell cycle into a resting state. Therefore, retinoid treatment may provide LCLs with the optimal conditions for an initial differentiative step, which ultimately results in the achievement of highly variable maturation features depending on intrinsic characteristics of each LCL.
It is well known that the proliferation of EBV-immortalized LCLs is driven by some EBV-encoded latent antigens, use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From in particular EBNA-2 and LMP-1.22,2' Interestingly, our results indicate that the antiproliferative activity exerted by retinoids on LCLs is not mediated by a direct effect of these compounds on the expression of EBNA-2 and LMP-1. In fact, after 3 days of retinoid treatment, when LCLs showed a significant decrease in DNA synthesis and growth rates, EBNA-2 and LMP-I expression levels were substantially unmodified or only slightly reduced. Nevertheless, after a longer period of treatment (6 days), various degrees of EBNA-2 and LMP-l downregulation were observed, with some LCLs showing a progressive decrease in viral antigen expression and other lines displaying almost unchanged levels even after 25 days of exposure to 13-cis-RA. These results seem to rule out that the antiproliferative effect of retinoids on LCLs may be consequent to a direct downregulation of EBV-encoded antigens exerted by these compounds. Consistent with such a hypothesis, we have observed that retinoids are also able to inhibit the in vitro growth of EBV-negative neoplastic B-cell lines (manuscript in preparation), although these fully transformed cells constitute an experimental model substantially different from LCLs. Our findings, although obtained on a limited number of cell lines, suggest that retinoids may indirectly induce a downregulation of latent EBV antigens. As for differentiation, these changes may also be consequent to the nonproliferating status reached by retinoid-treated LCLs, being part of the spectrum of spontaneous modifications occurring after exit from the cell cycle. On the other hand, since EBNA-2 and LMP-1 downregulation occurred in the cell lines showing more pronounced phenotypic and functional changes, the observed modulation of EBV antigen expression may be dependent on the differentiation characteristics achieved by EBV-infected B lymphocytes. Such a hypothesis is consistent with previous observations showing that EBV-infected B cells downregulate viral antigens concomitantly with cellular differentiation, both in ~i t r o~~.~' and in vivo."-4"
In conclusion, the results of the present study indicate that ( I ) retinoids significantly reduce the proliferation of EBVpositive LCLs, with 13-cis-RA, 9-cis-RA, and ATRA being the most effective compounds; (2) LCL growth arrest in vitro appears irreversible at retinoid concentrations ( I 0 h m o m ) that may be reached in man after oral drug administration; (3) treated cells show a progressive reduction in the S-phase compartment, associated with a concomitant upregdation of p27 Kip1 that inhibits G o G I transition; (4) the antiproliferative effect of retinoids is not dependent on the induction of terminal B-cell differentiation and is probably not mediated by a direct modulation of viral latent antigens; and ( 5 ) retinoids may indirectly induce various degrees of EBNA-2 and LMP-l downregulation.
The demonstration that retinoids exert a strong in vitro antiproliferative activity on EBV-positive LCLs opens an interesting area for future investigation that may have therapeutic implications. Particularly relevant in this regard is the possibility of using these compounds in the treatment of EBV-related lymphoproliferative disorders of immunosuppressed patients, for which lymphoblastoid cells represent a suitable experimental model. These diseases, in fact, often originate as nonmonoclonal cellular proliferations sustained by virus-immortalized B cells in the absence of an efficient immunosurveillance, and undergo mutational events only at later stages, facilitated by the high number of rapidly dividing cells. Therefore, since in our study retinoids have proved to efficaciously inhibit in vitro proliferation of EBV-infected cells at achievable and nontoxic doses without directly interfering with virus-cell interactions, these compounds may be useful in the medical treatment of lymphoproliferative disorders in the immunosuppressed host, especially in the earlier phases of the disease.
